Business
MetaStat, Inc. Appoints Michael J. Donovan, PhD, MD as Chief Medical Officer
MetaStat, Inc. Appoints Michael J. Donovan, PhD, MD as Chief Medical Officer.
About this update from Metastat Inc
[{"type":"text","content":"\n \n MetaStat, Inc. (OTCQB: MTST), a molecular diagnostic company focused on \n developing and commercializing epigenetic diagnostic tests for early and \n reliable prediction of systemic cancer metastasis, today announced the \n appointment of Michael J. Donovan, PhD, MD as acting Chief Medical \n Officer.\n \n \n Dr. Donovan joins the Company as the research and development program \n expands in breadth and depth for its proprietary driver-based diagnostic \n platform. MetaStat is applying a common pathway and underlying \n epigenetic factors that drive systemic metastasis to develop novel \n diagnostic tools aimed at personalizing cancer therapies and improving \n patient outcomes.\n \n \n “Michael’s training as a physician and PhD, combined with his extensive \n clinical development industry experience, expands our internal \n capabilities and brings a unique perspective that spans research and \n product development,” stated Douglas A. Hamilton, President and Chief \n Executive Officer of MetaStat. “We are fortunate to have access to \n Michael’s level of talent and look forward to his contribution as we \n build the body of clinical evidence in support of our MetaSite Breast \n and MenaCalc™ diagnostic product launches.”\n \n \n Dr. Donovan is board-certified in anatomic and clinical pathology and \n pediatric pathology with extensive experience in designing and \n implementing clinical studies. He has spearheaded the utilization of \n multiplex tissue and fluid-based assays and coupled mathematic \n applications to produce clinically relevant \n diagnostic/predictive/prognostic outcome models for a variety of tumor \n types and disease states. Dr. Donovan also serves as a Professor of \n Experimental Pathology and Director of the Biorepository and Pathology \n core at the Icahn School of Medicine at Mt. Sinai, New York City, New \n York.\n \n \n In addition to an academic career at Harvard Medical School and Boston \n Children’s Hospital, Dr. Donovan has over 20 years’ experience in the \n biotechnology industry, serving in various senior management roles at \n Millennium Pharmaceuticals and Incyte Pharmaceuticals. He most recently \n served as Chief Medical Officer of Exosome Diagnostics, Inc. and Chief \n Scientific Officer for Aureon Biosciences Corporation.\n \n \...